Outcomes from Unrelated Donor Hematopoietic Stem Cell Transplantation

Abstract

Background

Allogeneic hematopoietic cell transplantation (HCT) offers a curative treatment option for management of a variety of hematologic malignancies. While sibling donors have been the gold standard for adult patients in need of an HCT, not all patients have a suitable family donor. The availability of unrelated volunteer donor registries and alternative stem cell sources has expanded the wide application of this procedure.

Methods

PubMed and MEDLINE were searched for human trials and the English language from 2001 to 2011. Factors influencing transplantation outcomes involving unrelated donors over the last decade are discussed, and feasible alternative stem cell sources when a matched unrelated donor is not available are reviewed.

Results

HCT using a matched unrelated donor offers outcomes comparable to sibling HCT due to current molecular-based HLA typing and improvements in conditioning regimens and/or supportive care. The primary factor that contributes to improved outcome is the degree of donor-to-recipient HLA matching. The selection of younger unrelated donors has also been associated with improved outcomes in HCT. Evidence supports the universal application of matched unrelated donors even in high-risk leukemia and/or older patients. In adult patients without a matched related donor, other promising options as stem cell source includes mismatched unrelated donors, umbilical cord blood units, and haploidentical donors.

Conclusions

With current methodologies for molecular HLA typing and supportive care tools, outcomes of transplants with matched unrelated donors are comparable to those achieved with sibling donors. Alternative stem cell donors when a matched unrelated donor is not available are feasible expanding the stem cell donor pool.

References

Pasquini

M.C.

, Wang

. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR Summary Slides, 2010. http://www.cibmtr.org. Accessed June 16, 2011.

Gratwohl

, Baldomero

, Frauendorfer

. Results of the EBMT activity survey 2005 on haematopoietic stem cell transplantation: focus on increasing use of unrelated donors. Bone Marrow Transplant. 2007; 39(2): 71–87.

Lee

S.J.

, Anasetti

, Kuntz

K.M.

. The costs and cost-effectiveness of unrelated donor bone marrow transplantation for chronic phase chronic myelogenous leukemia. Blood. 1998; 92(11): 4047–4052.

de Lissovoy

, Hurd

, Carter

. Economic analysis of unrelated allogeneic bone marrow transplantation: results from the randomized clinical trial of T-cell depletion vs unmanipulated grafts for the prevention of graft-versushost disease. Bone Marrow Transplant. 2005; 36(6): 539–546.

Saito

A.M.

, Cutler

, Zahrieh

. Costs of allogeneic hematopoietic cell transplantation with high-dose regimens. Biol Blood Marrow Transplant. 2008; 14(2): 197–207.

Majhail

N.S.

, Mothukuri

J.M.

, Macmillan

M.L.

. Costs of pediatric allogeneic hematopoietic-cell transplantation. Pediatr Blood Cancer. 2010; 54(1): 138–143.

Skrepnek

G.H.

, Ballard

E.E.

. Cost-efficacy of imatinib versus allogeneic bone marrow transplantation with a matched unrelated donor in the treatment of chronic myelogenous leukemia: a decision-analytic approach. Pharmacotherapy. 2005; 25(3): 325–334.

Weisdorf

D.J.

, Anasetti

, Antin

J.H.

. Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation. Blood. 2002; 99(6): 1971–1977.

Moore

, Nivison-Smith

, Goh

. Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia. Biol Blood Marrow Transplant. 2007; 13(5): 601–607.

10.

Greinix

H.T.

, Nachbaur

, Krieger

. Factors affecting longterm outcome after allogeneic haematopoietic stem cell transplantation for acute myelogenous leukaemia: a retrospective study of 172 adult patients reported to the Austrian Stem Cell Transplantation Registry. Br J Haematol. 2002; 117(4): 914–923.

11.

Eapen

, Rubinstein

, Zhang

M.J.

. Comparable long-term survival after unrelated and HL-A-matched sibling donor hematopoietic stem cell transplantations for acute leukemia in children younger than 18 months. J Clin Oncol. 2006; 24(1): 145–151.

12.

Yakoub-Agha

, Mesnil

, Kuentz

. Allogeneic marrow stemcell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy. J Clin Oncol. 2006; 24(36): 5695–5702.

13.

Russell

J.A.

, Savoie

M.L.

, Balogh

. Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fludarabine, 400 CGY total-body irradiation, and thymoglobulin. Biol Blood Marrow Transplant. 2007; 13(7): 814–821.

14.

Wallen

, Gooley

T.A.

, Deeg

H.J.

. Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older. J Clin Oncol. 2005; 23(15): 3439–46.

15.

Shimoni

, Kröger

, Zabelina

. Hematopoietic stemcell transplantation from unrelated donors in elderly patients (age > 55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioning. Leukemia. 2005; 19(1): 7–12.

16.

van Besien

, Artz

, Stock

. Unrelated donor transplantation over the age of 55. Are we merely getting (b)older? Leukemia. 2005; 19(1): 31–33.

17.

Schetelig

, Bornhäuser

, Schmid

. Matched unrelated or matched sibling donors result in comparable survival after allogeneic stemcell transplantation in elderly patients with acute myeloid leukemia: a report from the cooperative German Transplant Study Group. J Clin Oncol. 2008; 26(32): 5183–5191.

18.

Woolfrey

, Lee

S.J.

, Gooley

T.A.

. HLA-allele matched unrelated donors compared to HLA-matched sibling donors: role of cell source and disease risk category. Biol Blood Marrow Transplant. 2010; 16(10): 1382–1387.

19.

Ringdén

, Pavletic

S.Z.

, Anasetti

. The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. Blood. 2009; 113(13): 3110–3118.

20.

Goldstone

A.H.

, Richards

S.M.

, Lazarus

H.M.

. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood. 2008; 111(4): 1827–1833.

21.

Davies

S.M.

, Mehta

P.A.

. Pediatric acute lymphoblastic leukemia: is there still a role for transplant? Hematology Am Soc Hematol Educ Program. 2010; 2010: 363–367.

22.

Nachman

J.B.

, La

M.K.

, Hunger

S.P.

. Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: a report from the Children's Oncology Group. J Clin Oncol. 2009; 27(31): 5189–5194.

23.

Hahn

, Wall

, Camitta

. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in adults: an evidence-based review. Biol Blood Marrow Transplant. 2006; 12(1): 1–30.

24.

Kiehl

M.G.

, Kraut

, Schwerdtfeger

. Outcome of allogeneic hematopoietic stemcell transplantation in adult patients with acute lympho-blastic leukemia: no difference in related compared with unrelated transplant in first complete remission. J Clin Oncol. 2004; 22(14): 2816–2825.

25.

Tomblyn

M.B.

, Arora

, Baker

K.S.

. Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: analysis of graft sources and long-term outcome. J Clin Oncol. 2009; 27(22): 3634–3641.

26.

Fielding

A.K.

, Richards

S.M.

, Chopra

. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood. 2007; 109(3): 944–950.

27.

Hahn

, McCarthy

P.L.

, Hassebroek

. Significant improvement in Day 100 and 1-year overall survival in patients who underwent myeloablative allogeneic hematopoietic cell transplant in the US or Canada between 1994 and 2005. Blood (ASH Annual Meeting Abstracts). 2010; 116: 3509. Abstract.

28.

Morishima

, Sasazuki

, Inoko

. The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. Blood. 2002; 99(11): 4200–4206.

29.

Petersdorf

E.W.

. HLA matching in allogeneic stem cell transplantation. Curr Opin Hematol. 2004; 11(6): 386–391.

30.

Flomenberg

, Baxter-Lowe

L.A.

, Confer

. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood. 2004; 104(7): 1923–1930.

31.

Lee

S.J.

, Klein

, Haagenson

. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood. 2007; 110(13): 4576–4583.

32.

Bray

R.A.

, Hurley

C.K.

, Kamani

N.R.

. National marrow donor program HLA matching guidelines for unrelated adult donor hematopoietic cell transplants. Biol Blood Marrow Transplant. 2008; 14(9 Suppl): 45–53.

33.

Ruggeri

, Capanni

, Urbani

. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002; 295(5562): 2097–2100.

34.

Farag

S.S.

, Bacigalupo

, Eapen

. The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry. Biol Blood Marrow Transplant. 2006; 12(8): 876–884.

35.

Cooley

, Trachtenberg

, Bergemann

T.L.

. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood. 2009; 113(3): 726–732.

36.

Cooley

, Weisdorf

D.J.

, Guethlein

L.A.

. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood. 2010; 116(14): 2411–2419.

37.

Kollman

, Howe

C.W.

, Anasetti

. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood. 2001; 98(7): 2043–2051.

38.

Ljungman

, Brand

, Einsele

. Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis. Blood. 2003; 102(13): 4255–2460.

39.

Confer

D.L.

, Abress

L.K.

, Navarro

. Selection of adult unrelated hematopoietic stem cell donors: beyond HLA. Biol Blood Marrow Transplant. 2010; 16(1 suppl): S8–S11.

40.

Kröger

, Zabelina

, van Biezen

. Donor selection for allogeneic stem cell transplantation in elderly patients with advanced MDS younger matched-unrelated donor or HLA-identical sibling? Blood (ASH Annual Meeting Abstracts. 2010; 116: 912. Abstract.

41.

Randolph

S.S.

, Gooley

T.A.

, Warren

E.H.

. Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLAmatched, related hematopoietic stem cell transplants. Blood. 2004; 103(1): 347–352.

42.

Allogeneic peripheral blood stemcell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. Stem Cell Trialists’ Collaborative Group.

J Clin Oncol. 2005; 23(22): 5074–5087.

43.

Lee

S.J.

, Kamani

, Confer

D.L.

. Principles and tools for selection of umbilical cord blood and unrelated adult donor grafts. Biol Blood Marrow Transplant. 2008; 14(1 suppl 1): 112–119.

44.

Horowitz

M.M.

. High-resolution typing for unrelated donor transplantation: how far do we go? Best Pract Res Clin Haematol. 2009; 22(4): 537–541.

45.

Laughlin

M.J.

, Eapen

, Rubinstein

. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med. 2004; 351(22): 2265–2275.

46.

Kumar

, De For

T.E.

, Brunstein

. Allogeneic hematopoietic stem cell transplantation in adult acute lymphocytic leukemia: impact of donor source on survival. Biol Blood Marrow Transplant. 2008; 14(12): 1394–1400.

47.

Eapen

, Rocha

, Sanz

. Effect of graft source on unrelated donor haemopoietic stemcell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol. 2010; 11(7): 653–660.

48.

Brunstein

C.G.

, Gutman

J.A.

, Weisdorf

D.J.

. Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood. 2010; 116(22): 4693–4699.

49.

Ballen

K.K.

, Spitzer

T.R.

. The great debate: haploidentical or cord blood transplant. Bone Marrow Transplant. 2011; 46(3): 323–329.

50.

Kanda

, Chao

N.J.

, Rizzieri

D.A.

. Haploidentical transplantation for leukemia. Curr Oncol Rep. 2010; 12(5): 292–301.

51.

Woolfrey

, Klein

J.P.

, Haagenson

. HLA-C antigen mismatch is associated with worse outcome in unrelated donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2011; 17(6): 885–892.

52.

Prentice

H.G.

, Blacklock

H.A.

, Janossy

. Depletion of T lymphocytes in donor marrow prevents significant graft-versushost disease in matched allogeneic leukaemic marrow transplant recipients. Lancet. 1984; 1(8375): 472–476.

53.

Wagner

J.E.

, Thompson

J.S.

, Carter

S.L.

. Effect of graft-versushost disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multicentre, randomised phase II-III trial. Lancet. 2005; 366(9487): 733–741.

54.

Jakubowski

A.A.

, Small

T.N.

, Kernan

N.A.

. T cell-depleted unrelated donor stem cell transplantation provides favorable disease-free survival for adults with hematologic malignancies. Biol Blood Marrow Transplant. 2011; 7(9): 1335–1342.

55.

Nash

R.A.

, Antin

J.H.

, Karanes

. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versushost disease after marrow transplantation from unrelated donors. Blood. 2000; 96(6): 2062–2068.

56.

Cutler

, Li

, Ho

V.T.

. Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood. 2007; 109(7): 3108–3114.

57.

Bacigalupo

, Oneto

, Lamparelli

. Preemptive therapy of acute graft-versushost disease: a pilot study with antithymocyte globulin (ATG). Bone Marrow Transplant. 2001; 28(12): 1093–1096.

58.

Bacigalupo

, Lamparelli

, Gualandi

. Prophylactic antithymocyte globulin reduces the risk of chronic graft-versushost disease in alternative-donor bone marrow transplants. Biol Blood Marrow Transplant. 2002; 8(12): 656–661.

59.

Bacigalupo

, Lamparelli

, Bruzzi

. Antithymocyte globulin for graft-versushost disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood. 2001; 98(10): 2942–2947.

60.

Pidala

, Tomblyn

, Nishihori

. ATG prevents severe acute graft-versushost disease in mismatched unrelated donor hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011; 17(8): 1237–1244.

61.

Kumar

, Mhaskar

A.R.

, Kharfan-Dabaja

. Antithymocyte globulin (ATG) for graft-versus-host-disease (GvHD) prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation (alloHCT): a systematic review and meta-analysis. Blood (ASH Annual Meeting Abstracts). 2010; 116: 1513.